{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T08:46:07Z","timestamp":1795250767708,"version":"4.10.3"},"reference-count":121,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1097\/tp.0000000000001447","type":"journal-article","created":{"date-parts":[[2016,8,19]],"date-time":"2016-08-19T21:20:39Z","timestamp":1471641639000},"page":"45-55","source":"Crossref","is-referenced-by-count":127,"title":["Cancer and mTOR Inhibitors in Transplant Recipients"],"prefix":"10.1097","volume":"101","author":[{"given":"Johan W.","family":"de Fijter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20210211","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"R3-15-20210211","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/sj.bjc.6601219","article-title":"Cancer risk following organ transplantation: a nationwide cohort study in Sweden","volume":"89","author":"Adami","year":"2003","journal-title":"Br J Cancer"},{"key":"R4-15-20210211","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.296.23.2823","article-title":"Cancer incidence before and after kidney transplantation","volume":"296","author":"Vajdic","year":"2006","journal-title":"JAMA"},{"key":"R5-15-20210211","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1600-6143.2007.01736.x","article-title":"Cancer incidence among Canadian kidney transplant recipients","volume":"7","author":"Villeneuve","year":"2007","journal-title":"Am J Transplant"},{"key":"R6-15-20210211","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1111\/j.1600-6143.2010.03181.x","article-title":"Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit","volume":"10","author":"Collett","year":"2010","journal-title":"Am J Transplant"},{"key":"R7-15-20210211","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.canep.2010.07.002","article-title":"Incidence of cancer in kidney-transplant recipients: a long-term cohort study in a single center","volume":"35","author":"Wisgerhof","year":"2011","journal-title":"Cancer Epidemiol"},{"key":"R8-15-20210211","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1681\/ASN.2015040373","article-title":"Variation in cancer incidence among patients with ESRD during kidney function and nonfunction Intervals","volume":"27","author":"Yanik","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"R9-15-20210211","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1002\/ijc.24439","article-title":"Cancer incidence and risk factors after solid organ transplantation","volume":"125","author":"Vajdic","year":"2009","journal-title":"Int J Cancer"},{"key":"R10-15-20210211","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet"},{"key":"R11-15-20210211","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/ajt.12969","article-title":"Sirolimus use and cancer incidence among US kidney transplant recipients","volume":"15","author":"Yanik","year":"2015","journal-title":"Am J Transplant"},{"key":"R12-15-20210211","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1600-6143.2012.04302.x","article-title":"Comparison of de novo cancer incidence in Australian liver, heart and lung transplant recipients","volume":"13","author":"Na","year":"2013","journal-title":"Am J Transplant"},{"key":"R13-15-20210211","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1600-6143.2009.02973.x","article-title":"The incidence of cancer in a population-based cohort of Canadian heart transplant recipients","volume":"10","author":"Jiang","year":"2010","journal-title":"Am J Transplant"},{"key":"R14-15-20210211","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"},{"key":"R15-15-20210211","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/01.tp.0000209921.60305.d9","article-title":"Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma","volume":"81","author":"Euvrard","year":"2006","journal-title":"Transplantation"},{"key":"R16-15-20210211","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1097\/TP.0b013e3181d84cdc","article-title":"Subsequent squamous- and basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: cumulative incidence and risk factors","volume":"89","author":"Wisgerhof","year":"2010","journal-title":"Transplantation"},{"key":"R17-15-20210211","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jaad.2005.10.049","article-title":"Clinicopathologic features of skin cancer in organ transplant recipients: a retrospective case-control series","volume":"54","author":"Harwood","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"R18-15-20210211","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/j.1600-6143.2011.03589.x","article-title":"A case-control study of betapapillomavirus infection and cutaneous squamous cell carcinoma in organ transplant recipients","volume":"11","author":"Proby","year":"2011","journal-title":"Am J Transplant"},{"key":"R19-15-20210211","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/01.TP.0000184006.43152.8D","article-title":"Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies","volume":"80","author":"Kauffman","year":"2005","journal-title":"Transplantation"},{"key":"R20-15-20210211","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: a target for cancer therapy","volume":"4","author":"Bjornsti","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"R21-15-20210211","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1111\/j.1600-6143.2008.02391.x","article-title":"mTOR, cancer and transplantation","volume":"8","author":"Geissler","year":"2008","journal-title":"Am J Transplant"},{"key":"R22-15-20210211","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/01.tp.0000219703.39149.85","article-title":"Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials","volume":"81","author":"Webster","year":"2006","journal-title":"Transplantation"},{"key":"R23-15-20210211","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1200\/JCO.2008.20.0766","article-title":"Targeting the mTOR signaling network for cancer therapy","volume":"27","author":"Meric-Bernstam","year":"2009","journal-title":"J Clin Oncol"},{"key":"R24-15-20210211","doi-asserted-by":"crossref","first-page":"g6679","DOI":"10.1136\/bmj.g6679","article-title":"Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data","volume":"349","author":"Knoll","year":"2014","journal-title":"BMJ"},{"key":"R25-15-20210211","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/cam4.487","article-title":"Sirolimus effects on cancer incidence after kidney transplantation: a meta-analysis","volume":"4","author":"Yanik","year":"2015","journal-title":"Cancer Med"},{"key":"R26-15-20210211","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nrm1018","article-title":"Tor signalling in bugs, brain and brawn","volume":"4","author":"Jacinto","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R27-15-20210211","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","article-title":"mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery","volume":"110","author":"Kim","year":"2002","journal-title":"Cell"},{"key":"R28-15-20210211","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/nyas.12756","article-title":"mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging","volume":"1346","author":"Perl","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"R29-15-20210211","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1097-2765(02)00568-3","article-title":"Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase\/Akt pathway","volume":"10","author":"Manning","year":"2002","journal-title":"Mol Cell"},{"key":"R30-15-20210211","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev"},{"key":"R31-15-20210211","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0960-9822(03)00506-2","article-title":"Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb","volume":"13","author":"Tee","year":"2003","journal-title":"Curr Biol"},{"key":"R32-15-20210211","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1126\/science.273.5272.239","article-title":"Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP","volume":"273","author":"Choi","year":"1996","journal-title":"Science"},{"key":"R33-15-20210211","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor","volume":"8","author":"Guba","year":"2002","journal-title":"Nat Med"},{"key":"R34-15-20210211","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1101\/gad.1617608","article-title":"Hypoxia regulates TSC1\/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling","volume":"22","author":"DeYoung","year":"2008","journal-title":"Genes Dev"},{"key":"R35-15-20210211","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"R36-15-20210211","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.molmed.2007.08.001","article-title":"Targeting the mTOR signaling network in cancer","volume":"13","author":"Chiang","year":"2007","journal-title":"Trends Mol Med"},{"key":"R37-15-20210211","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1042\/BJ20080281","article-title":"The TSC1-TSC2 complex: a molecular switchboard controlling cell growth","volume":"412","author":"Huang","year":"2008","journal-title":"Biochem J"},{"key":"R38-15-20210211","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ejca.2005.03.023","article-title":"Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes","volume":"41","author":"Jiang","year":"2005","journal-title":"Eur J Cancer"},{"key":"R39-15-20210211","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/1471-2407-8-163","article-title":"Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma","volume":"8","author":"Chakraborty","year":"2008","journal-title":"BMC Cancer"},{"key":"R40-15-20210211","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1083\/jcb.200408161","article-title":"Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis","volume":"167","author":"Manning","year":"2004","journal-title":"J Cell Biol"},{"key":"R41-15-20210211","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1038\/onc.2009.352","article-title":"Common corruption of the mTOR signaling network in human tumors","volume":"27","author":"Menon","year":"2008","journal-title":"Oncogene"},{"key":"R42-15-20210211","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1200\/JCO.2008.21.5988","article-title":"Pancreatic endocrine tumors: expression profiling evidences a role for Akt-mTOR pathway","volume":"28","author":"Missiaglia","year":"2010","journal-title":"J Clin Oncol"},{"key":"R43-15-20210211","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1200\/JCO.2010.34.4879","article-title":"Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer","volume":"29","author":"Miller","year":"2011","journal-title":"J Clin Oncol"},{"key":"R44-15-20210211","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"R45-15-20210211","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"R46-15-20210211","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejim.2006.07.017","article-title":"Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex","volume":"18","author":"Herry","year":"2007","journal-title":"Eur J Intern Med"},{"key":"R47-15-20210211","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N Engl J Med"},{"key":"R48-15-20210211","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"R49-15-20210211","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1101\/gad.1199104","article-title":"Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome","volume":"18","author":"Corradetti","year":"2004","journal-title":"Genes Dev"},{"key":"R50-15-20210211","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1073\/pnas.0503224102","article-title":"The NF1 tumor suppressor critically regulates TSC2 and mTOR","volume":"102","author":"Johannessen","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R51-15-20210211","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa042831","article-title":"Sirolimus for Kaposi's sarcoma in renal-transplant recipients","volume":"352","author":"Stallone","year":"2005","journal-title":"N Engl J Med"},{"key":"R52-15-20210211","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/01.TP.0000115344.18025.0B","article-title":"Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma","volume":"77","author":"Campistol","year":"2004","journal-title":"Transplantation"},{"key":"R53-15-20210211","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.trre.2008.05.004","article-title":"Kaposi sarcoma in transplantation","volume":"22","author":"Lebbe","year":"2008","journal-title":"Transplant Rev (Orlando"},{"key":"R54-15-20210211","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2004.05.061","article-title":"Role of VHL gene mutation in human cancer","volume":"22","author":"Kim","year":"2004","journal-title":"J Clin Oncol"},{"key":"R55-15-20210211","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"R56-15-20210211","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"R57-15-20210211","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"R58-15-20210211","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.hoc.2011.05.001","article-title":"Future directions in renal cell carcinoma: 2011 and beyond","volume":"25","author":"Cho","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"R59-15-20210211","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/sj.ki.5002154","article-title":"The janus face of immunosuppression\u2014de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich","volume":"71","author":"Wimmer","year":"2007","journal-title":"Kidney Int"},{"key":"R60-15-20210211","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"R61-15-20210211","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1200\/JCO.2005.23.622","article-title":"Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study","volume":"23","author":"Galanis","year":"2005","journal-title":"J Clin Oncol"},{"key":"R62-15-20210211","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/cncr.21265","article-title":"CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium","volume":"104","author":"Margolin","year":"2005","journal-title":"Cancer"},{"key":"R63-15-20210211","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1200\/JCO.2005.66.130","article-title":"Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer","volume":"23","author":"Chan","year":"2005","journal-title":"J Clin Oncol"},{"key":"R64-15-20210211","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/JCO.2008.21.3033","article-title":"Randomized phase II study comparing two schedules of everolimus in patients with recurrent\/metastatic breast cancer: NCIC Clinical Trials Group IND.163","volume":"27","author":"Ellard","year":"2009","journal-title":"J Clin Oncol"},{"key":"R65-15-20210211","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.it.2014.11.005","article-title":"Regulation of T cells by mTOR: the known knowns and the known unknowns","volume":"36","author":"Pollizzi","year":"2015","journal-title":"Trends Immunol"},{"key":"R66-15-20210211","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1600-6143.2010.03407.x","article-title":"Sirolimus enhances the magnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in rhesus macaques","volume":"11","author":"Turner","year":"2011","journal-title":"Am J Transplant"},{"key":"R67-15-20210211","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/rmv.1733","article-title":"Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms","volume":"23","author":"Brennan","year":"2013","journal-title":"Rev Med Virol"},{"key":"R68-15-20210211","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1097\/01.tp.0000290232.65830.e7","article-title":"A quantitative assay for Epstein-Barr virus-specific immunity shows interferon-gamma producing CD8+ T cells increase during immunosuppression reduction to treat posttransplant lymphoproliferative disease","volume":"84","author":"Guppy","year":"2007","journal-title":"Transplantation"},{"key":"R69-15-20210211","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1073\/pnas.080068597","article-title":"The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders","volume":"97","author":"Majewski","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R70-15-20210211","doi-asserted-by":"crossref","first-page":"8225","DOI":"10.4049\/jimmunol.179.12.8225","article-title":"Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL-10","volume":"179","author":"Lambert","year":"2007","journal-title":"J Immunol"},{"key":"R71-15-20210211","first-page":"4472","article-title":"Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas","volume":"63","author":"Nepomuceno","year":"2003","journal-title":"Cancer Res"},{"key":"R72-15-20210211","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1097\/01.tp.0000260142.38619.9c","article-title":"Rapamycin inhibits proliferation of Epstein-Barr virus-positive B-cell lymphomas through modulation of cell-cycle protein expression","volume":"83","author":"Vaysberg","year":"2007","journal-title":"Transplantation"},{"key":"R73-15-20210211","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1111\/j.1600-6143.2007.01972.x","article-title":"Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab","volume":"7","author":"Kirk","year":"2007","journal-title":"Am J Transplant"},{"key":"R74-15-20210211","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1084\/jem.20071477","article-title":"The Akt-mTOR axis regulates de novo differentiation of CD4 + Foxp3+ cells","volume":"205","author":"Haxhinasto","year":"2008","journal-title":"J Exp Med"},{"key":"R75-15-20210211","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/PDM.0b013e31804f54a9","article-title":"Gene expression profiling of Epstein-Barr virus-positive and -negative monomorphic B-cell posttransplant lymphoproliferative disorders","volume":"16","author":"Craig","year":"2007","journal-title":"Diagn Mol Pathol"},{"key":"R76-15-20210211","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1600-0609.2008.01106.x","article-title":"Proteomics analysis in post-transplant lymphoproliferative disorders","volume":"81","author":"Alsayed","year":"2008","journal-title":"Eur J Haematol"},{"key":"R77-15-20210211","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1126\/science.282.5395.1837","article-title":"The enigmas of Kaposi's sarcoma","volume":"282","author":"Gallo","year":"1998","journal-title":"Science"},{"key":"R78-15-20210211","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1200\/JCO.1997.15.6.2371","article-title":"Treatment of Kaposi's sarcoma after solid organ transplantation","volume":"15","author":"Shepherd","year":"1997","journal-title":"J Clin Oncol"},{"key":"R79-15-20210211","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1172\/JCI26666","article-title":"The human herpesvirus 8 chemokine receptor vGPCR triggers autonomous proliferation of endothelial cells","volume":"116","author":"Grisotto","year":"2006","journal-title":"J Clin Invest"},{"key":"R80-15-20210211","first-page":"4873","article-title":"The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha","volume":"60","author":"Sodhi","year":"2000","journal-title":"Cancer Res"},{"key":"R81-15-20210211","doi-asserted-by":"crossref","first-page":"14363","DOI":"10.1073\/pnas.1001065107","article-title":"Viral G protein-coupled receptor up-regulates Angiopoietin-like 4 promoting angiogenesis and vascular permeability in Kaposi's sarcoma","volume":"107","author":"Ma","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R82-15-20210211","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.healun.2006.01.010","article-title":"Sirolimus for Kaposi's sarcoma","volume":"25","author":"Wasywich","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"R83-15-20210211","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1038\/jid.2011.91","article-title":"Transcriptome sequencing demonstrates that human papillomavirus is not active in cutaneous squamous cell carcinoma","volume":"131","author":"Arron","year":"2011","journal-title":"J Invest Dermatol"},{"key":"R84-15-20210211","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/ijc.11691","article-title":"Mechanisms of genomic instability in human Cancer: insights from studies with human papillomavirus oncoproteins","volume":"109","author":"Duensing","year":"2004","journal-title":"Int J Cancer"},{"key":"R86-15-20210211","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1681\/ASN.2015091021","article-title":"Cancer in ESRD: Clear on the Epidemiology, Hazy on the Mechanisms","volume":"27","author":"Lim","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"R87-15-20210211","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1097\/TP.0b013e3181ff1458","article-title":"Patient survival after the diagnosis of cancer in renal transplant recipients: a nested case-control study.","volume":"90","author":"van de Wetering","year":"2010","journal-title":"Transplantation"},{"key":"R88-15-20210211","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/jamaoncol.2015.5137","article-title":"Cancer mortality among recipients of solid-organ transplantation in Ontario, Canada","volume":"2","author":"Acuna","year":"2016","journal-title":"JAMA Oncol"},{"key":"R89-15-20210211","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/j.1600-6143.2009.02728.x","article-title":"Cancer mortality in kidney transplantation","volume":"9","author":"Kiberd","year":"2009","journal-title":"Am J Transplant"},{"key":"R90-15-20210211","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/ki.2013.458","article-title":"Malignancy-related mortality following kidney transplantation is common","volume":"85","author":"Farrugia","year":"2014","journal-title":"Kidney Int"},{"key":"R91-15-20210211","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/ajt.12716","article-title":"Survival after cutaneous melanoma in kidney transplant recipients: a population-based matched cohort study","volume":"14","author":"Vajdic","year":"2014","journal-title":"Am J Transplant"},{"key":"R92-15-20210211","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/rr.2000.5269","article-title":"Cancers in renal transplant recipients","volume":"7","author":"Penn","year":"2000","journal-title":"Adv Ren Replace Ther"},{"key":"R93-15-20210211","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-4632.2010.04370.x","article-title":"Basal cell carcinoma in a series of renal transplant recipients: epidemiology and clinicopathologic features","volume":"49","author":"Mertz","year":"2010","journal-title":"Int J Dermatol"},{"key":"R94-15-20210211","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMra022137","article-title":"Skin cancers after organ transplantation","volume":"348","author":"Euvrard","year":"2003","journal-title":"N Engl J Med"},{"key":"R95-15-20210211","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/00007890-199003000-00006","article-title":"Incidence of skin cancer after renal transplantation in The Netherlands","volume":"49","author":"Hartevelt","year":"1990","journal-title":"Transplantation"},{"key":"R96-15-20210211","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/01.tp.0000269707.06060.dc","article-title":"Seven-year prospective study of nonmelanoma skin cancer incidence in U.K. renal transplant recipients","volume":"84","author":"Ramsay","year":"2007","journal-title":"Transplantation"},{"key":"R97-15-20210211","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1097\/TP.0b013e3181a5ce2e","article-title":"Predicting risk of nonmelanoma skin cancer and premalignant skin lesions in renal transplant recipients","volume":"87","author":"Urwin","year":"2009","journal-title":"Transplantation"},{"key":"R98-15-20210211","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jaad.2005.07.061","article-title":"Skin cancer in organ transplant recipients: effect of pretransplant end-organ disease","volume":"53","author":"Otley","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"R99-15-20210211","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/17401","article-title":"Cyclosporine induces cancer progression by a cell-autonomous mechanism","volume":"397","author":"Hojo","year":"1999","journal-title":"Nature"},{"key":"R100-15-20210211","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1600-0625.2011.01413.x","article-title":"Skin cancer in organ transplant recipients: effects of immunosuppressive medications on DNA repair","volume":"21","author":"Kuschal","year":"2012","journal-title":"Exp Dermatol"},{"key":"R101-15-20210211","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1126\/science.1114233","article-title":"Azathioprine and UVA light generate mutagenic oxidative DNA damage","volume":"309","author":"O'Donovan","year":"2005","journal-title":"Science"},{"key":"R102-15-20210211","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/j.1600-6143.2012.04004.x","article-title":"Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer","volume":"12","author":"Campbell","year":"2012","journal-title":"Am J Transplant"},{"key":"R103-15-20210211","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMoa1204166","article-title":"Sirolimus and secondary skin-cancer prevention in kidney transplantation","volume":"367","author":"Euvrard","year":"2012","journal-title":"N Engl J Med"},{"key":"R104-15-20210211","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.2012.45.6376","article-title":"Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus","volume":"31","author":"Hoogendijk-van den Akker","year":"2013","journal-title":"J Clin Oncol"},{"key":"R105-15-20210211","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/ijc.27765","article-title":"Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008\u2014a Swedish population-based study","volume":"132","author":"Krynitz","year":"2013","journal-title":"Int J Cancer"},{"key":"R106-15-20210211","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.trre.2012.07.001","article-title":"New concepts and best practices for management of pre- and post-transplantation cancer","volume":"26","author":"Campistol","year":"2012","journal-title":"Transplant Rev (Orlando"},{"key":"R107-15-20210211","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/TP.0b013e3182247ae2","article-title":"Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial","volume":"92","author":"Alberu","year":"2011","journal-title":"Transplantation"},{"key":"R108-15-20210211","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1681\/ASN.2005090993","article-title":"Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation","volume":"17","author":"Campistol","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R109-15-20210211","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic renal failure after transplantation of a nonrenal organ","volume":"349","author":"Ojo","year":"2003","journal-title":"N Engl J Med"},{"key":"R110-15-20210211","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/TP.0000000000000965","article-title":"Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial","volume":"100","author":"Geissler","year":"2016","journal-title":"Transplantation"},{"key":"R111-15-20210211","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2217\/fon.15.70","article-title":"Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review","volume":"11","author":"Huang","year":"2015","journal-title":"Future Oncol"},{"key":"R112-15-20210211","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1158\/1078-0432.CCR-10-2285","article-title":"Dual mTORC2\/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors","volume":"17","author":"Altman","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R113-15-20210211","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1097\/00007890-199911270-00016","article-title":"Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group","volume":"68","author":"Kahan","year":"1999","journal-title":"Transplantation"},{"key":"R114-15-20210211","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0140-6736(00)02480-6","article-title":"Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group","volume":"356","author":"Kahan","year":"2000","journal-title":"Lancet"},{"key":"R115-15-20210211","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/TP.0b013e318291a269","article-title":"A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients","volume":"95","author":"Flechner","year":"2013","journal-title":"Transplantation"},{"key":"R116-15-20210211","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/j.1600-6143.2011.03573.x","article-title":"The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients","volume":"11","author":"Flechner","year":"2011","journal-title":"Am J Transplant"},{"key":"R117-15-20210211","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/TP.0b013e3181927a41","article-title":"Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial","volume":"87","author":"Schena","year":"2009","journal-title":"Transplantation"},{"key":"R118-15-20210211","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1681\/ASN.2010111160","article-title":"Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation","volume":"22","author":"Sharif","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R119-15-20210211","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/ajt.12795","article-title":"A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients","volume":"14","author":"Lim","year":"2014","journal-title":"Am J Transplant"},{"key":"R120-15-20210211","doi-asserted-by":"crossref","first-page":"e65166","DOI":"10.1371\/journal.pone.0065166","article-title":"Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis","volume":"8","author":"Qi","year":"2013","journal-title":"PLoS One"},{"key":"R121-15-20210211","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1681\/ASN.2009101043","article-title":"Long-term cancer risk of immunosuppressive regimens after kidney transplantation","volume":"21","author":"Gallagher","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R122-15-20210211","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0140-6736(97)08496-1","article-title":"Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens","volume":"351","author":"Dantal","year":"1998","journal-title":"Lancet"},{"key":"R123-15-20210211","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/01.tp.0000176945.10520.40","article-title":"Genitourinary malignancies in solid organ transplant recipients","volume":"80","author":"Muruve","year":"2005","journal-title":"Transplantation"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00007890-201701000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T19:17:53Z","timestamp":1646421473000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201701000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":121,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000001447","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}